Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden.
Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, CB2 0AA Cambridge, U.K.
ACS Synth Biol. 2022 Jul 15;11(7):2229-2237. doi: 10.1021/acssynbio.2c00106. Epub 2022 Jul 7.
Rapid and flexible plasmid construct generation at scale is one of the most limiting first steps in drug discovery projects. These hurdles can partly be overcome by adopting modular DNA design principles, automated sequence fragmentation, and plasmid assembly. To this end we have designed a robust, multimodule based cloning platform for construct generation with a wide range of applications. The assembly efficiency of the system was validated by splitting and cassettes and expressing them in followed by fluorometric assessment. To minimize timelines and cost for complex constructs, we developed a software tool named FRAGLER (FRAGment recycLER) that performs codon optimization, multiple sequence alignment, and automated generation of fragments for recycling. To highlight the flexibility and robustness of the platform, we (i) generated plasmids for SarsCoV2 protein reagents, (ii) automated and parallelized assemblies, and (iii) built modular libraries of chimeric antigen receptors (CARs) variants. Applying the new assembly framework, we have greatly streamlined plasmid construction and increased our capacity for rapid generation of complex plasmids.
快速灵活的大规模质粒构建是药物发现项目中最具挑战性的第一步之一。通过采用模块化 DNA 设计原则、自动化序列片段化和质粒组装,可以部分克服这些障碍。为此,我们设计了一个稳健的、基于多模块的克隆平台,用于构建具有广泛应用的质粒。该系统的组装效率通过分割和片段并在中表达,然后进行荧光评估进行了验证。为了最小化复杂构建体的时间线和成本,我们开发了一个名为 FRAGLER(FRAGment recycLER)的软件工具,该工具执行密码子优化、多重序列比对和片段的自动生成以进行回收。为了突出该平台的灵活性和稳健性,我们 (i) 生成了用于 SARS-CoV2 蛋白试剂的质粒,(ii) 自动化和并行化组装,以及 (iii) 构建了嵌合抗原受体 (CAR) 变体的模块化文库。应用新的组装框架,我们大大简化了质粒构建,提高了快速生成复杂质粒的能力。